Table 3 Quality of evidence according to GRADE approach
Certainty assessment | № of patients | Effect | Certainty | Importance | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
№ of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | n-3 PUFA | control | Relative (95% CI) | Absolute (95% CI) | |||
BW | |||||||||||||
6 | randomised trials | not serious | not serious | not serious | very seriousa,b | none | 185 | 186 | - | MD 1.49 lower (4.12 lower to 1.14 higher) | ⨁⨁◯◯ Low | NOT IMPORTANT | |
BMI | |||||||||||||
10 | randomised trials | not serious | not serious | not serious | not serious | none | 376 | 380 | - | MD 0.56 lower (1.11 lower to 0.01 lower) | ⨁⨁⨁⨁ High | NOT IMPORTANT | |
WC | |||||||||||||
3 | randomised trials | not serious | not serious | not serious | seriousa | none | 112 | 114 | - | MD 2.76 lower (3.82 lower to 1.69 lower) | ⨁⨁⨁◯ Moderate | NOT IMPORTANT | |
FPG | |||||||||||||
6 | randomised trials | not serious | not serious | not serious | seriousa | none | 176 | 179 | - | MD 3.91 lower (5.69 lower to 2.13 lower) | ⨁⨁⨁◯ Moderate | IMPORTANT | |
FINS | |||||||||||||
6 | randomised trials | not serious | not serious | not serious | not serious | none | 230 | 233 | - | MD 2.45 lower (3.19 lower to 1.71 lower) | ⨁⨁⨁⨁ High | IMPORTANT | |
HOMA-IR | |||||||||||||
6 | randomised trials | seriousc | not serious | not serious | not serious | publication bias strongly suspectedc | 230 | 233 | - | MD 0.45 lower (0.8 lower to 0.11 lower) | ⨁⨁◯◯ Low | IMPORTANT | |
QUICKI | |||||||||||||
3 | randomised trials | seriousc | not serious | not serious | seriousa | publication bias strongly suspectedc | 91 | 91 | - | MD 0.01 higher (0.01 higher to 0.02 higher) | ⨁◯◯◯ Very low | IMPORTANT | |
Adiponectin | |||||||||||||
3 | randomised trials | seriousc | not serious | not serious | seriousa | publication bias strongly suspectedc | 166 | 168 | - | MD 1.46 higher (1.12 higher to 1.8 higher) | ⨁◯◯◯ Very low | IMPORTANT | |
TG | |||||||||||||
7 | randomised trials | not serious | not serious | not serious | not serious | none | 273 | 277 | - | MD 9.33 lower (10.56 lower to 8.1 lower) | ⨁⨁⨁⨁ High | IMPORTANT | |
TC | |||||||||||||
7 | randomised trials | seriousc | not serious | not serious | not serious | publication bias strongly suspectedc | 273 | 277 | - | MD 12.32 lower (19.15 lower to 5.5 lower) | ⨁⨁◯◯ Low | IMPORTANT | |
HDL-C | |||||||||||||
7 | randomised trials | seriousc | seriousd | not serious | seriousb | publication bias strongly suspectedc | 273 | 277 | - | MD 2.1 higher (0.29 lower to 4.5 higher) | ⨁◯◯◯ Very low | IMPORTANT | |
LDL-C | |||||||||||||
7 | randomised trials | seriousc | not serious | not serious | not serious | publication bias strongly suspectedc | 273 | 277 | - | MD 10.53 lower (19.31 lower to 1.75 lower) | ⨁⨁◯◯ Low | IMPORTANT | |
VLDL-C | |||||||||||||
3 | randomised trials | not serious | not serious | not serious | very seriousa,b | none | 91 | 91 | - | MD 2.33 lower (5.9 lower to 1.23 higher) | ⨁⨁◯◯ Low | IMPORTANT | |
hs-CRP | |||||||||||||
6 | randomised trials | seriousc | not serious | not serious | very seriousa,b | publication bias strongly suspectedc | 159 | 161 | - | MD 0.56 lower (1.19 lower to 0.07 higher) | ⨁◯◯◯ Very low | IMPORTANT | |